Capricor Therapeutics is trading at $7.41 in after-hours trading, up 16.20% from the October 30 regular-session close of $6.38; no confirmed catalyst has been identified.
- The latest company press release found was dated October 5 and reported positive HOPE-3 extension data.
- Broader markets were sharply lower, so market sentiment does not clearly explain the move.
- The November 22 FDA decision remains upcoming and is not a confirmed explanation.